CL2011002467A1 - Compuestos derivados de 6-(3-aza-biciclo[3.1.0]hex-3-il)-2-fenilpirimidinas, antagonistas del receptor p2y 12; composicion farmaceutica que los comprende; y su uso en el tratamiento de trastornos oclusivos. pct fase nacional. - Google Patents

Compuestos derivados de 6-(3-aza-biciclo[3.1.0]hex-3-il)-2-fenilpirimidinas, antagonistas del receptor p2y 12; composicion farmaceutica que los comprende; y su uso en el tratamiento de trastornos oclusivos. pct fase nacional.

Info

Publication number
CL2011002467A1
CL2011002467A1 CL2011002467A CL2011002467A CL2011002467A1 CL 2011002467 A1 CL2011002467 A1 CL 2011002467A1 CL 2011002467 A CL2011002467 A CL 2011002467A CL 2011002467 A CL2011002467 A CL 2011002467A CL 2011002467 A1 CL2011002467 A1 CL 2011002467A1
Authority
CL
Chile
Prior art keywords
phenylpyrimidines
aza
bicyclo
hex
antagonists
Prior art date
Application number
CL2011002467A
Other languages
English (en)
Inventor
Kurt Hilpert
Francis Hubler
Eva Carof
Emmanuel Meyer
Dorte Renneberg
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of CL2011002467A1 publication Critical patent/CL2011002467A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

Compuestos derivados de 6-(3-aza-biciclo[3.1.0]hex-3-il)-2-fenilpirimidinas, antagonistas del receptor de adenosina 5'-difosfato (adp); composición farmacéutica; y su uso para eltratamiento de trastornos vasculares oclusivos.
CL2011002467A 2009-04-08 2011-10-04 Compuestos derivados de 6-(3-aza-biciclo[3.1.0]hex-3-il)-2-fenilpirimidinas, antagonistas del receptor p2y 12; composicion farmaceutica que los comprende; y su uso en el tratamiento de trastornos oclusivos. pct fase nacional. CL2011002467A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IB2009051486 2009-04-08

Publications (1)

Publication Number Publication Date
CL2011002467A1 true CL2011002467A1 (es) 2012-02-24

Family

ID=42936647

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011002467A CL2011002467A1 (es) 2009-04-08 2011-10-04 Compuestos derivados de 6-(3-aza-biciclo[3.1.0]hex-3-il)-2-fenilpirimidinas, antagonistas del receptor p2y 12; composicion farmaceutica que los comprende; y su uso en el tratamiento de trastornos oclusivos. pct fase nacional.

Country Status (18)

Country Link
US (1) US8288385B2 (es)
EP (1) EP2417128B1 (es)
JP (1) JP5536873B2 (es)
KR (1) KR101694563B1 (es)
CN (1) CN102369197B (es)
AU (1) AU2010233378A1 (es)
BR (1) BRPI1014039A2 (es)
CA (1) CA2756542C (es)
CL (1) CL2011002467A1 (es)
ES (1) ES2567311T3 (es)
IL (1) IL215517A0 (es)
MA (1) MA33260B1 (es)
MX (1) MX2011010200A (es)
NZ (1) NZ596213A (es)
RU (1) RU2011144763A (es)
SG (1) SG175075A1 (es)
WO (1) WO2010116328A2 (es)
ZA (1) ZA201108158B (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10988463B2 (en) 2015-12-29 2021-04-27 Pfizer Inc. Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200640877A (en) 2005-04-28 2006-12-01 Actelion Pharmaceuticals Ltd Pyrimidine derivatives
AR063258A1 (es) 2006-10-13 2009-01-14 Actelion Pharmaceuticals Ltd Derivados de 2-aminocarbonil-piridina, una composicion farmaceutica que los contiene y su uso en la preparacion de un medicamento para el tratamiento de trastornos vasculares oclusivos.
AR063518A1 (es) 2006-10-25 2009-01-28 Actelion Pharmaceuticals Ltd Derivados 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y su uso para tratar y/o prevenir enfermedades vasculares perifericas viscerales, hepaticas y renales, enfermedades cardiovasculares y enfermedades cerebrovasculares asociados con la agregacion de plaquetas, incluyendo trombosis
RU2483072C2 (ru) 2007-11-29 2013-05-27 Актелион Фармасьютиклз Лтд Производные фосфоновой кислоты и их применение в качестве антагонистов рецептора p2y12
AR071653A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2-fenil-4-ciclopropil-pirimidina
AR071652A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2- fenil-piridina substituidos
ES2469847T3 (es) 2009-04-22 2014-06-20 Actelion Pharmaceuticals Ltd. Derivados de tiazol y su uso como antagonistas del receptor P2Y12
EA201400976A1 (ru) 2012-03-06 2015-02-27 Бёрингер Ингельхайм Интернациональ Гмбх Бензодиоксаны в комбинации с другими активными средствами для ингибирования продуцирования лейкотриена
WO2014145548A2 (en) * 2013-03-15 2014-09-18 Concert Medical, Llc Method and system for controllably administering fluid to a patient and/or for controllably withdrawing fluid from the patient
KR102388621B1 (ko) 2016-08-31 2022-04-21 에자이 알앤드디 매니지먼트 가부시키가이샤 피라졸로[1,5-a]피리미딘 화합물
CN109715639B (zh) 2016-09-22 2022-04-19 爱杜西亚药品有限公司 结晶形式
MA49887A (fr) 2017-03-15 2020-06-24 Idorsia Pharmaceuticals Ltd Administration sous-cutanée d'un antagoniste du récepteur p2y12
KR20220034739A (ko) 2019-05-31 2022-03-18 이케나 온콜로지, 인코포레이티드 Tead 억제제 및 이의 용도
GB202001856D0 (en) * 2020-02-11 2020-03-25 Inorbit Therapeutics Ab Compounds useful in inhibiting ketohexokinase and methods of making and using the same

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5373586A (en) 1976-12-09 1978-06-30 Mitsubishi Chem Ind Ltd New penicillin derivatives
US6861424B2 (en) * 2001-06-06 2005-03-01 Schering Aktiengesellschaft Platelet adenosine diphosphate receptor antagonists
DE60333866D1 (de) * 2002-12-11 2010-09-30 Bayer Schering Pharma Ag 2-aminocarbonlyl-chinolin-verbindungen als adenosin diphosphat plättchenrezeptor antagonisten
WO2004092189A1 (en) 2003-04-09 2004-10-28 Wyeth Derivatives of 2-(8,9-dioxo-2,6-diazabicyclo(5.2.0)non-1(7)-en-2-yl)alkyl phosphonic acid and their use as n-methyl-d-aspartate (nmda) recetor antagonists
TW200640877A (en) * 2005-04-28 2006-12-01 Actelion Pharmaceuticals Ltd Pyrimidine derivatives
AR057836A1 (es) 2005-10-21 2007-12-19 Actelion Pharmaceuticals Ltd Piperizinas como agentes contra la malaria
EP2066645A2 (en) * 2006-09-12 2009-06-10 UCB Pharma S.A. 2 amino-pyrimidine derivatives as h4 receptor antagonists, processes for preparing them and their use in pharmaceutical compositions
AR063258A1 (es) 2006-10-13 2009-01-14 Actelion Pharmaceuticals Ltd Derivados de 2-aminocarbonil-piridina, una composicion farmaceutica que los contiene y su uso en la preparacion de un medicamento para el tratamiento de trastornos vasculares oclusivos.
AR063518A1 (es) 2006-10-25 2009-01-28 Actelion Pharmaceuticals Ltd Derivados 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y su uso para tratar y/o prevenir enfermedades vasculares perifericas viscerales, hepaticas y renales, enfermedades cardiovasculares y enfermedades cerebrovasculares asociados con la agregacion de plaquetas, incluyendo trombosis
MX2009011089A (es) 2007-04-23 2009-10-30 Sanofi Aventis Derivados de quinolina-carboxamida en calidad de antagonistas de p2y12.
WO2009004383A2 (en) * 2007-07-03 2009-01-08 Astrazeneca Ab Aza-bicyclohexane compounds useful as anticoagulants
RU2483072C2 (ru) 2007-11-29 2013-05-27 Актелион Фармасьютиклз Лтд Производные фосфоновой кислоты и их применение в качестве антагонистов рецептора p2y12
EP2238128B1 (en) 2007-12-26 2012-08-22 Sanofi Heterocyclic pyrazole-carboxamides as p2y12 antagonists
EP2238127B1 (en) 2007-12-26 2012-08-15 Sanofi Pyrazole-carboxamide derivatives as p2y12 antagonists
AR071652A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2- fenil-piridina substituidos
AR071653A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2-fenil-4-ciclopropil-pirimidina
ES2469847T3 (es) 2009-04-22 2014-06-20 Actelion Pharmaceuticals Ltd. Derivados de tiazol y su uso como antagonistas del receptor P2Y12

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10988463B2 (en) 2015-12-29 2021-04-27 Pfizer Inc. Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors
US11634410B2 (en) 2015-12-29 2023-04-25 Pfizer Inc. Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors

Also Published As

Publication number Publication date
WO2010116328A2 (en) 2010-10-14
NZ596213A (en) 2013-05-31
JP5536873B2 (ja) 2014-07-02
US8288385B2 (en) 2012-10-16
ZA201108158B (en) 2014-04-30
SG175075A1 (en) 2011-11-28
KR20120070627A (ko) 2012-06-29
CN102369197B (zh) 2013-11-06
MX2011010200A (es) 2011-10-14
KR101694563B1 (ko) 2017-01-09
EP2417128A2 (en) 2012-02-15
BRPI1014039A2 (pt) 2018-04-03
IL215517A0 (en) 2011-12-29
US20120028989A1 (en) 2012-02-02
CA2756542A1 (en) 2010-10-14
CN102369197A (zh) 2012-03-07
MA33260B1 (fr) 2012-05-02
WO2010116328A3 (en) 2011-01-13
ES2567311T3 (es) 2016-04-21
CA2756542C (en) 2017-08-22
JP2012523406A (ja) 2012-10-04
EP2417128B1 (en) 2016-03-02
RU2011144763A (ru) 2013-05-20
AU2010233378A1 (en) 2011-11-24

Similar Documents

Publication Publication Date Title
CL2011002467A1 (es) Compuestos derivados de 6-(3-aza-biciclo[3.1.0]hex-3-il)-2-fenilpirimidinas, antagonistas del receptor p2y 12; composicion farmaceutica que los comprende; y su uso en el tratamiento de trastornos oclusivos. pct fase nacional.
DOP2010000234A (es) Antagonistas n,n-disustituidos de aminoalquilbifenilo de receptores d2 de prostaglandina
CL2009000873A1 (es) Compuestos derivados de ciclohepta[b]piridina, antagonistas del receptor de cgrp; composicion farmaceutica; y uso para el tratamiento de la migrana.b
UY31619A1 (es) Compuestos espiro como antagonistas del receptor npy y5
DOP2014000115A (es) Uso de 4-fenil-piridinas sustituidas para la fabricación de medicamentos útiles en el tratamiento de enfermedades relacionadas con el receptor de nk1
CL2012003293A1 (es) Compuestos derivados de aminopirimidina, como moduladores de la proteina quinasa rica en repeticiones leucina 2 (lrrk2); composicion farmaceutica que los contiene; y su uso para el tratamiento terapeutico y/o profilactico de la enfermedad de parkinson.
UY28766A1 (es) Compuestos heteropolicíclicos adicionales y su uso como antagonistas del receptor de glutamato metabotrópico
UY32036A (es) Derivados de ciclohexil-amida, composiciones farmacéuticas que los contienen, su preparación y aplicaciones
CL2011002942A1 (es) Compuestos derivados de 2,4-diamino-pirimidina, agonistas de receptor tipo toll-7 (tlr7); composicion farmaceutica; y su uso para el tratamiento del cancer.
CR10309A (es) "compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1"
IN2012DN02735A (es)
IN2012DN02730A (es)
IN2012DN00754A (es)
MY163055A (en) Polycyclic antagonists of lysophosphatidic acid receptors
CL2008003188A1 (es) Compuestos derivados de piridina y pirazina; composicion farmaceutica que los comprende;y su uso en el tratamiento o prevencion de tumores sensibles a la inhibicion de enzimas del receptor ax1 y/o c-met.
CL2013002517A1 (es) Compuestos derivados de fosforoamidato de 5-fluoro-2'-desoxiuridina; procedimiento de preparacion; composicion farmaceutica que los comprende; su uso en el tratamiento o profilaxis del cancer.
ECSP099250A (es) USO DE 2-6-(3-amino-piperidin-1-Il)-3-metil-2,4-dioxo-3,4-dihIdro-2H-pIrimidin-1-IlmetIL-4-fluoro-benzonitrilo
ECSP077421A (es) Compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1
CL2012000591A1 (es) Compuestos derivados de pirimidina o 1,3,5-triazina, antagonistas de hepcidina; composicion farmaceutica; combinacion farmaceutica util en el tratamiento de desordenes del metabolismo del hierro y los sintomas asociados.
EA201071291A2 (ru) Nmda рецепторные антагонисты для лечения нейропсихиатрических расстройств
UY32327A (es) Antagonistas de receptores de ácido lisofosfatídico
CR20110103A (es) Heteroarilos sustituidos
CR11854A (es) Compuestos de piridina
CL2013003816A1 (es) Compuestos derivados de carboxamida y urea que comprende pirazol aromatico sustituido, ligantes del receptor de vanilloide; composicion farmaceutica que los comprende; y su uso en el tratamiento y/o profilaxis del dolor, migraña, enfermedad de parkinson, trastornos gastrointestinales, osteoporosis, entre otras enfermedades.
CR10497A (es) Derivados de piperazinilo utiles en el tratamiento de enfermedades mediadas por el receptor gpr38